Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $103.92M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.84M
Average 0.54M
VYGR Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Voyager Therapeutics, Inc.NASDAQ: VYGR
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital declines year over year
Q1 FY2026 change in working capital of $9.81M (cash outflow) fell 17.0% year over year, ahead of the -37.9% change in trailing-twelve-month change in working capital. Sequentially, it rose 41.3% from the prior quarter.
Context
- Change in working capital amounted to 71.2% of revenue in FY2025, up 27.7 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -17.0% holds above the trailing-twelve-month pace of -37.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (28.76M) USD
- Year-over-year change
- -182.5%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.76M) | -182.5% |
| FY2024 | 2024-12-31 | 34.86M | +152.4% |
| FY2023 | 2023-12-31 | (66.56M) | -425.1% |
| FY2022 | 2022-12-31 | 20.47M | +521.5% |
| FY2021 | 2021-12-31 | 3.29M | — |
Change in Working Capital vs competitors
How VYGR compares with its peers on the latest reported figures
- VYGR's LTM Mar 2026 change in working capital of $26.75M is the 2nd largest of the 11 companies compared; the peer median is $2.25M.
- Its year-over-year change of -37.9% is the 7th highest of 11, against a peer median of +115.1%.
- Change in working capital amounts to 73.3% of revenue for VYGR, versus a peer median of 34.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.76M | +146.8% | +80.5% | 50.2% | |
| LTM Mar 2026 | $26.75M | -37.9% | — | 73.3% | |
| LTM Mar 2026 | $15.79M | +1014.2% | — | — | |
| LTM Mar 2026 | $15.14M | +208.6% | — | 750.8% | |
| LTM Mar 2026 | $14.08M | +115.1% | -24.4% | 245.3% | |
| LTM Mar 2026 | $13.89M | +159.9% | — | — | |
| LTM Mar 2026 | $8.51M | -85.7% | +46.2% | 18.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $3.42M | -181.2% | — | — |
| LTM Mar 2026 | $2.34M | +115.1% | +11.0% | 1.1% | |
| LTM Mar 2026 | $2.15M | -59.7% | -24.4% | 15.5% | |
| LTM Mar 2026 | $531K | -62.5% | — | — | |
| Peer median (excluding VYGR) | $2.25M | +115.1% | +11.0% | 34.5% | |
Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (46.41M) | 132.33M | (65M) | (119.72M) |
| Depreciation & Amortization | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.32M | 9.34M | 11.15M | 14.79M | 14.79M |
| Change in Working Capital | 3.29M | 20.47M | (66.56M) | 34.86M | (28.76M) |
| Accounts Receivables | 7.28M | 475K | (83.23M) | 81.31M | 268K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (60K) | 1.99M | (962K) | 2.39M | 1.02M |
| Other Working Capital | (3.93M) | 18M | 17.64M | (48.84M) | (30.05M) |
| Other Non-Cash Items | (2.11M) | (2.11M) | (3.45M) | (4.68M) | (2.83M) |
| Operating Cash Flow | (53.53M) | (12.51M) | 77.92M | (15.31M) | (132.47M) |
| Capital Expenditures | (1.61M) | (2.49M) | (3.26M) | (3.52M) | (2.6M) |
| Acquisitions (Net) | 0 | 0 | 138.39M | 0 | 0 |
| Purchases of Investments | (15.12M) | (54.85M) | (223.97M) | (465.69M) | (133.93M) |
| Sales of Investments | 82.63M | 50M | 85.58M | 374.35M | 261.97M |
| Other Investing Activities | 0 | 0 | (138.39M) | 0 | 0 |
| Investing Cash Flow | 65.91M | (7.34M) | (141.64M) | (94.86M) | 125.45M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Effect of Forex Changes | 0 | 264K | 0 | 0 | 0 |
| Net Change in Cash | 12.99M | (18.47M) | (30.08M) | 3.85M | (6.21M) |
| Free Cash Flow | (55.13M) | (15M) | 74.66M | (18.83M) | (135.06M) |
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Intrinsic Alpha fair value
Locked
Current Price
$1.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.